首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TPO |
| Uniprot No | P07202-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-846aa |
| 氨基酸序列 | MRALAVLSVT LVMACTEAFF PFISRGKELL WGKPEESRVS SVLEESKRLV DTAMYATMQR NLKKRGILSP AQLLSFSKLP EPTSGVIARA AEIMETSIQA MKRKVNLKTQ QSQHPTDALS EDLLSIIANM SGCLPYMLPP KCPNTCLANK YRPITGACNN RDHPRWGASN TALARWLPPV YEDGFSQPRG WNPGFLYNGF PLPPVREVTR HVIQVSNEVV TDDDRYSDLL MAWGQYIDHD IAFTPQSTSK AAFGGGADCQ MTCENQNPCF PIQLPEEARP AAGTACLPFY RSSAACGTGD QGALFGNLST ANPRQQMNGL TSFLDASTVY GSSPALERQL RNWTSAEGLL RVHARLRDSG RAYLPFVPPR APAACAPEPG IPGETRGPCF LAGDGRASEV PSLTALHTLW LREHNRLAAA LKALNAHWSA DAVYQEARKV VGALHQIITL RDYIPRILGP EAFQQYVGPY EGYDSTANPT VSNVFSTAAF RFGHATIHPL VRRLDASFQE HPDLPGLWLH QAFFSPWTLL RGGGLDPLIR GLLARPAKLQ VQDQLMNEEL TERLFVLSNS STLDLASINL QRGRDHGLPG YNEWREFCGL PRLETPADLS TAIASRSVAD KILDLYKHPD NIDVWLGGLA ENFLPRARTG PLFACLIGKQ MKALRDGDWF WWENSHVFTD AQRRELEKHS LSRVICDNTG LTRVPMDAFQ VGKFPEDFES CDSITGMNLE AWRETFPQDD KCGFPESVEN GDFVHCEESG RRVLVYSCRH GYELQGREQL TCTQEGWDFQ PPLCKDVNEC ADGAHPPCHA SARCRNTKGG FQCLCADPYE LGDDGRTCVD SGRLPR |
| 预测分子量 | 94 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TPO(血小板生成素)重组蛋白的模拟参考文献示例(内容为虚构概括，仅供参考)：
---
1. **《重组人血小板生成素在大肠杆菌中的高效表达及生物活性研究》**
*作者：Souyri M, et al. (1994)*
**摘要**：首次报道通过基因工程技术在大肠杆菌中表达功能性重组人TPO蛋白，证实其能特异性激活巨核细胞增殖并促进血小板生成。
2. **《PEG修饰TPO类似物在血小板减少症模型中的长效治疗效果》**
*作者：Cwirla SE, et al. (2002)*
**摘要**：开发聚乙二醇化重组TPO变体(PEG-rhTPO)，显著延长半衰期，在动物模型中单次给药即可持续提升血小板水平，降低给药频率。
3. **《重组TPO联合化疗药物治疗肿瘤相关性血小板减少的临床前评估》**
*作者：Kato T, et al. (2000)*
**摘要**：在化疗诱导的血小板减少小鼠模型中，重组TPO可加速血小板恢复，且与化疗药物联用未影响抗肿瘤疗效，支持其临床转化潜力。
4. **《哺乳动物细胞表达系统优化生产重组TPO的工艺开发》**
*作者：Zhang Y, et al. (2018)*
**摘要**：采用CHO细胞表达体系，通过载体优化和培养条件调控实现重组TPO的高产稳性生产，为工业化制备奠定基础。
---
注：以上文献信息为示例性概括，实际研究请通过学术数据库(如PubMed、Web of Science)检索具体文献。
**Background of Recombinant Thrombopoietin (TPO) Protein**
Thrombopoietin (TPO), a key regulator of platelet production, is a glycoprotein hormone primarily produced in the liver and kidneys. Discovered in 1994. TPO binds to the c-Mpl receptor on megakaryocytes and hematopoietic stem cells, stimulating their proliferation, differentiation, and maturation into platelets. This process is critical for maintaining hemostasis and responding to thrombocytopenic conditions.
Native TPO consists of two domains: an N-terminal receptor-binding domain and a C-terminal carbohydrate-rich domain that enhances stability. However, early recombinant TPO formulations (e.g., recombinant human TPO) faced challenges, including immunogenicity and cross-reactivity with endogenous TPO, leading to neutralizing antibodies and thrombocytopenia in some patients. These issues prompted the development of TPO mimetics and receptor agonists as safer alternatives.
Recombinant TPO proteins, such as romiplostim (a peptibody with TPO-mimetic domains) and eltrombopag (a small-molecule c-Mpl agonist), revolutionized thrombocytopenia treatment. Unlike endogenous TPO, these agents avoid immune-mediated clearance while effectively boosting platelet counts. They are FDA-approved for chronic immune thrombocytopenia (ITP) and hepatitis C-associated thrombocytopenia, reducing reliance on platelet transfusions.
Advances in protein engineering, including PEGylation and Fc-fusion techniques, have improved the pharmacokinetics and stability of recombinant TPO products. Ongoing research explores their potential in chemotherapy-induced thrombocytopenia and myelodysplastic syndromes. Additionally, gene therapy approaches aim to enable sustained TPO expression, offering long-term solutions for congenital platelet disorders.
Despite progress, challenges remain in optimizing dosing regimens and minimizing off-target effects. Future directions include designing next-generation TPO analogs with enhanced specificity and exploring combination therapies to address multifactorial causes of thrombocytopenia. Overall, recombinant TPO proteins represent a cornerstone in hematology, bridging molecular biology insights with clinical innovation.
×
